Tech Company Financing Transactions
bit.bio Funding Round
On 11/4/2026, bit.bio landed $25 million in Series D investment from private investors and M&G Investments.
Transaction Overview
Company Name
Announced On
11/4/2026
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series D
Investors
private investors (Jonathan Milner)
Proceeds Purpose
The company intends to use the funds to expand its portfolio of human cell types, increase market availability, and support wider customer access.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Dorothy Hodgkin Building, Babraham Research Campus
Cambridge, CB22 3FH
UK
Cambridge, CB22 3FH
UK
Phone
Website
Email Address
Overview
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox�; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. The company has expertise in the underpinning science of synthetic biology and stem cells, manufacturing, and clinical translation. The board is chaired by Lord David Prior.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/4/2026: Sporta venture capital transaction
Next: 11/4/2026: Lazzaro One venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








